Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BioAtla Inc.
BCAB | US
4.31
USD-0.15
-3.36%
BCAB | US
About BioAtla Inc.
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
13/04/2026
Close
4.31
Open
4.50
High
5.22
Low
4.31
BioAtla Inc. a clinical stage biopharmaceutical company develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011 a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors non-small cell lung cancer (NSCLC) and ovarian cancer. It also develops BA3021 a CAB ADC for multiple solid tumor types including NSCLC melanoma and head and neck cancer; and BA3071 which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma NSCLC small cell lung cancer hepatocellular carcinoma melanoma bladder cancer gastric cancer and cervical cancer. BioAtla Inc. was founded in 2007 and is based in San Diego California.
View LessBCAB | US
Risk
131.0
Sharpe
-0.57
Luna's Score
43/100
Recommendation
Sell
Luna says (BCAB | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
123.3%1 month
131.0%3 months
152.8%6 months
155.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.85
Debt to equity
0.05
Debt to assets
0.02
Ent. to EBITDA
0.31
Ent. to rev.
134.37
PEG
-
Other Fundamentals
EBITDA
-108.88M
MarketCap
208.33M
MarketCap(USD)
208.33M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
31.60
Ret. on equity
-134.14
Short ratio
7.70
Short perc.
10.33
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
6.40
Range1M
6.40
Range3M
6.40
Volumes: Market Activity
Rel. volume
1.03
Price X volume
212.72K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.31 | - | Cheaper |
| Ent. to Revenue | 134.37 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.85 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 152.77 | - | Riskier |
| Debt to Equity | 0.05 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 208.33M | - | Emerging |
